CLLS NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Cellectis SA · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 2.84 USD
8.0% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -20.9% below the Trend Line and sits at 13.4% of its 52-week range. The latest completed week returned 8.0%, after a 0.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is mixed with 24/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.

Setup score 19 out of 100
Latest Close 2.84 USD 24 Jul 2026
1W Return 8.0% latest completed week
4W Return 0.4% short-term follow-through
12W Return -28.1% quarterly tape
Trend Breadth 59.6% 31 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Price is above Fair Value, showing premium demand versus the model.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Activity pressure is negative, which weakens the current setup.
  • Next-week expectancy is negative at 40.92% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.0% Latest completed week; four-week move 0.4%. Indicator stack 33/20 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.92% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Mixed 24/100 conviction; expected move 45.6%. News sentiment 52/100 54 relevant articles in the latest sentiment read. Event risk 2d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -20.9% below the Trend Line and sits at 13.4% of its 52-week range. The latest completed week returned 8.0%, after a 0.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.20

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 0.4% over four weeks, -28.1% over 12 weeks, and 12.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W8.0%
4W0.4%
12W-28.1%
26W-35.7%
52W12.7%
Active trend streak0 weeks
Active weeks in one year31
Trend breadth59.6%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.11Latest activity-pressure read.
Pressure change-131.3%Four-week change in activity pressure.
Leadership-28.13Latest relative-leadership reading.
RS change5.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength7/100Blend of value, momentum, and quality. Underlying universe rank 94; rank 1 is best.
Value21/100Relative valuation strength. Underlying universe rank 80; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum35/100Medium-term price momentum. Underlying universe rank 66; rank 1 is best.
Growth86/100Revenue and earnings growth. Underlying universe rank 15; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
4.2x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-9.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
81.9%
Gross profit retained from each unit of revenue.
Operating margin
-104.0%
Operating profit retained from revenue.
Free-cash-flow margin
-52.4%
Free cash flow generated from revenue.
Return on invested capital
-39.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
42.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-207.7%
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.0%
Cash dividends relative to market value.
Buyback yield
-0.0%
Net share repurchases relative to market value.
Shareholder yield
-0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningMixed

CLLS shows mixed options pressure with a 24/100 conviction score, put-call volume ratio of n/a, expected move of 45.6%, and Sharemaestro trend signal inactive.

Conviction24/100
Expected move45.6%
Put/call volume
Pressure4
Speculation0
Volatility96
Trend agreement50
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 54 relevant articles.

6 positive · 46 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings2dNext report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
Options expected move45.6%Nearest-chain priced movement where available.
52-week drawdown-48.2%Distance below the 52-week high.
13-week volatility8.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+23.1%Week of 17 Apr.
Worst week-14.3%Week of 30 Jan.
Latest week+8.0%Week of 24 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks0
Modest losses5
Sharp losses10
Recent vol8.1%13-week weekly-return volatility.
Base vol9.8%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew9.3% / -7.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis11/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 1/12.

Activity pressure 0.07; No reversal markers Next-Week ExpectancyNegative 40.92%

Next-week expectancy is negative with a 40.92% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors16/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 69; Small Cap Core rank 81 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

CLLS shows mixed options pressure with a 24/100 conviction score, put-call volume ratio of n/a, expected move of 45.6%, and Sharemaestro trend signal inactive.

Mixed · Options-market disagreement · Expected move 45.6% Sentiment52/100

Weighted news tone is neutral across 54 relevant articles.

Cellectis SA expected to post a loss of 26 cents a share - Earnings Preview Insiders50/100

No recent insider transaction evidence is stored.

 Earnings2d

Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20262.84 USD8.0%3.59 USD2.59 USD-1.11-28.1363.5KOff
17 Jul 20262.63 USD-12.0%3.65 USD2.58 USD-0.97-34.58109.2KOff
10 Jul 20262.99 USD-9.4%3.71 USD2.59 USD-0.76-28.5965.2KOff
3 Jul 20263.30 USD16.6%3.77 USD2.58 USD-0.55-19.4391.6KOff
26 Jun 20262.83 USD-5.0%3.82 USD2.57 USD-0.48-29.89153.0KOff
19 Jun 20262.98 USD-3.6%3.89 USD2.57 USD-0.29-29.17187.3KOff
12 Jun 20263.09 USD1.0%3.95 USD2.56 USD-0.18-24.28316.0KOff
5 Jun 20263.06 USD-13.1%3.98 USD2.55 USD-0.07-22.83337.2KOff
29 May 20263.52 USD0.6%3.98 USD2.55 USD-0.03-14.74191.7KOff
22 May 20263.50 USD-10.7%3.98 USD2.54 USD-0.06-12.18154.1KOff
15 May 20263.92 USD1.8%3.98 USD2.53 USD-0.080.24143.8KOff
8 May 20263.85 USD-2.5%3.98 USD2.51 USD-0.00-1.0194.1KOff
1 May 20263.95 USD1.5%3.99 USD2.50 USD-0.297.9773.7KOff
24 Apr 20263.89 USD-12.0%3.97 USD2.49 USD-0.548.97119.2KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.